Amphotericin B deoxycholate

First approved in 1958

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C47H73NO17.C24H39O4.Na
Molecular Weight	1338.6328
Optical Activity	UNSPECIFIED
Defined Stereocenters	29 / 29
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure of Amphotericin B deoxycholate

Structure Search

SMILES

[Na+].C[C@H](CCC([O-])=O)[C@H]1CC[C@H]2[C@@H]3CC[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3C[C@H](O)[C@]12C.C[C@H]5O[C@@H](O[C@@H]6C[C@@H]7O[C@@](O)(C[C@H](O)[C@H]7C(O)=O)C[C@@H](O)C[C@@H](O)[C@H](O)CC[C@@H](O)C[C@@H](O)CC(=O)O[C@@H](C)[C@H](C)[C@H](O)[C@@H](C)\C=C\C=C\C=C\C=C\C=C\C=C\C=C\6)[C@@H](O)[C@@H](N)[C@@H]5O

InChI

InChIKey=NFHDUMMQBQTVTR-OXEBIIQQSA-M

InChI=1S/C47H73NO17.C24H40O4.Na/c1-27-17-15-13-11-9-7-5-6-8-10-12-14-16-18-34(64-46-44(58)41(48)43(57)30(4)63-46)24-38-40(45(59)60)37(54)26-47(61,65-38)25-33(51)22-36(53)35(52)20-19-31(49)21-32(50)23-39(55)62-29(3)28(2)42(27)56;1-14(4-9-22(27)28)18-7-8-19-17-6-5-15-12-16(25)10-11-23(15,2)20(17)13-21(26)24(18,19)3;/h5-18,27-38,40-44,46,49-54,56-58,61H,19-26,48H2,1-4H3,(H,59,60);14-21,25-26H,4-13H2,1-3H3,(H,27,28);/q;;+1/p-1/b6-5+,9-7+,10-8+,13-11+,14-12+,17-15+,18-16+;;/t27-,28-,29-,30+,31+,32+,33-,34-,35+,36+,37-,38-,40+,41-,42+,43+,44-,46-,47+;14-,15-,16-,17+,18-,19+,20+,21+,23+,24-;/m01./s1

HIDE SMILES / InChI

Molecular Formula	Na
Molecular Weight	22.98976928
Charge	1
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	C24H39O4
Molecular Weight	391.5641
Charge	-1
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	10 / 10
E/Z Centers	0
Optical Activity	UNSPECIFIED

Molecular Formula	C47H73NO17
Molecular Weight	924.079
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	19 / 19
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/22869574http://www.x-gen.us/wp-content/uploads/sites/21/2014/03/XGSS_TSM_AMPH.03.15.pdf
Curator's Comment: Description was created based on several sources, including: http://www.drugs.com/monograph/amphotericin-b.html https://en.wikipedia.org/wiki/Amphotericin_B#cite_note-45 http://www.drugbank.ca/drugs/DB00681

Amphotericin B used to treat progressive, potentially life-threatening fungal infections, such as oral thrush, vaginal candidiasis and esophageal candidiasis in patients with normal neutrophil counts. Also, Amphotericin B is often used in otherwise-untreatable protozoan infections such as visceral leishmaniasis and primary amoebic meningoencephalitis. As with other polyene antifungals, amphotericin B binds with ergosterol, a component of fungal cell membranes, forming a transmembrane channel that leads to monovalent ion (K+, Na+, H+ and Cl−) leakage, which is the primary effect leading to fungal cell death. When administered concurrently, the following drugs may interact with amphotericin B: Antineoplastic agents, Corticosteroids and Corticotropin (ACTH); Digitalis glycosides; Flucytosine; Imidazoles (e.g., ketoconazole, miconazole, clotrimazole, fluconazole, etc.); Zidovudine; Skeletal muscle relaxants (tubocurarine); Rifabutin; Leukocyte transfusions. The adverse reactions most commonly observed are: fever; malaise; weight loss; hypotension; tachypnea; anorexia; nausea; vomiting; diarrhea; dyspepsia; cramping epigastric pain; normochromic, normocytic anemia; pain at the injection site with or without phlebitis or thrombophlebitis; generalized pain, including muscle and joint pains; headache; decreased renal function and renal function abnormalities.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Ergosterol 7 Target ID: CHEMBL2364028 Sources: http://www.ncbi.nlm.nih.gov/pubmed/19689243	Binding Agent 1076
cell wall organization 4 Target ID: GO:0071555 Sources: https://www.aceabiotech.com/corifungin/ \| https://www.ncbi.nlm.nih.gov/pubmed/24366747	Interacts 323

Conditions

Condition	Modality	Highest Phase	Product
Mycoses 12 Sources: https://www.aceabiotech.com/corifungin/ https://www.aceabiotech.com/clinical-development-of-corifungin/	Curative	Preclinical	Unknown Approved Use Unknown
Naeglerias 3 Sources: https://www.ncbi.nlm.nih.gov/pubmed/22869574 https://www.aceabiotech.com/corifungin/	Curative	Preclinical	Unknown Approved Use Unknown
Cryptococcosis 4 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/050740s021lbl.pdf	Curative	Approved 8583	AMPHOTERICIN B Approved Use Amphotericin B for Injection USP should be administered primarily to patients with progressive, potentially life-threatening fungal infections. This potent drug should not be used to treat noninvasive fungal infections, such as oral thrush, vaginal candidiasis and esophageal candidiasis in patients with normal neutrophil counts. Amphotericin B for Injection USP is specifically intended to treat potentially life-threatening fungal infections: aspergillosis, cryptococcosis (torulosis), North American blastomycosis, systemic candidiasis, coccidioido-mycosis, histoplasmosis, zygomycosis including mucormycosis due to susceptible species of the genera Absidia, Mucor and Rhizopus, and infections due to related susceptible species of Conidiobolus and Basidiobolus, and sporotrichosis. Amphotericin B may be useful in the treatment of American mucocutaneous leishmaniasis, but it is not the drug of choice as primary therapy. Launch Date 1992
Blastomycosis 7 Sources: http://www.x-gen.us/wp-content/uploads/sites/21/2014/03/XGSS_TSM_AMPH.03.15.pdf	Curative	Approved 8583	AMPHOTERICIN B Approved Use Amphotericin B for Injection USP should be administered primarily to patients with progressive, potentially life-threatening fungal infections. This potent drug should not be used to treat noninvasive fungal infections, such as oral thrush, vaginal candidiasis and esophageal candidiasis in patients with normal neutrophil counts. Amphotericin B for Injection USP is specifically intended to treat potentially life-threatening fungal infections: aspergillosis, cryptococcosis (torulosis), North American blastomycosis, systemic candidiasis, coccidioido-mycosis, histoplasmosis, zygomycosis including mucormycosis due to susceptible species of the genera Absidia, Mucor and Rhizopus, and infections due to related susceptible species of Conidiobolus and Basidiobolus, and sporotrichosis. Amphotericin B may be useful in the treatment of American mucocutaneous leishmaniasis, but it is not the drug of choice as primary therapy. Launch Date 1992
Candida infections 20 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/050740s021lbl.pdf	Curative	Approved 8583	AMPHOTERICIN B Approved Use Amphotericin B for Injection USP should be administered primarily to patients with progressive, potentially life-threatening fungal infections. This potent drug should not be used to treat noninvasive fungal infections, such as oral thrush, vaginal candidiasis and esophageal candidiasis in patients with normal neutrophil counts. Amphotericin B for Injection USP is specifically intended to treat potentially life-threatening fungal infections: aspergillosis, cryptococcosis (torulosis), North American blastomycosis, systemic candidiasis, coccidioido-mycosis, histoplasmosis, zygomycosis including mucormycosis due to susceptible species of the genera Absidia, Mucor and Rhizopus, and infections due to related susceptible species of Conidiobolus and Basidiobolus, and sporotrichosis. Amphotericin B may be useful in the treatment of American mucocutaneous leishmaniasis, but it is not the drug of choice as primary therapy. Launch Date 1992
Visceral leishmaniasis 6 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/050740s021lbl.pdf	Curative	Approved 8583	AMPHOTERICIN B Approved Use Amphotericin B for Injection USP should be administered primarily to patients with progressive, potentially life-threatening fungal infections. This potent drug should not be used to treat noninvasive fungal infections, such as oral thrush, vaginal candidiasis and esophageal candidiasis in patients with normal neutrophil counts. Amphotericin B for Injection USP is specifically intended to treat potentially life-threatening fungal infections: aspergillosis, cryptococcosis (torulosis), North American blastomycosis, systemic candidiasis, coccidioido-mycosis, histoplasmosis, zygomycosis including mucormycosis due to susceptible species of the genera Absidia, Mucor and Rhizopus, and infections due to related susceptible species of Conidiobolus and Basidiobolus, and sporotrichosis. Amphotericin B may be useful in the treatment of American mucocutaneous leishmaniasis, but it is not the drug of choice as primary therapy. Launch Date 1992
Coccidioidomycosis 5 Sources: http://www.x-gen.us/wp-content/uploads/sites/21/2014/03/XGSS_TSM_AMPH.03.15.pdf	Curative	Approved 8583	AMPHOTERICIN B Approved Use Amphotericin B for Injection USP should be administered primarily to patients with progressive, potentially life-threatening fungal infections. This potent drug should not be used to treat noninvasive fungal infections, such as oral thrush, vaginal candidiasis and esophageal candidiasis in patients with normal neutrophil counts. Amphotericin B for Injection USP is specifically intended to treat potentially life-threatening fungal infections: aspergillosis, cryptococcosis (torulosis), North American blastomycosis, systemic candidiasis, coccidioido-mycosis, histoplasmosis, zygomycosis including mucormycosis due to susceptible species of the genera Absidia, Mucor and Rhizopus, and infections due to related susceptible species of Conidiobolus and Basidiobolus, and sporotrichosis. Amphotericin B may be useful in the treatment of American mucocutaneous leishmaniasis, but it is not the drug of choice as primary therapy. Launch Date 1992
Histoplasmosis 5 Sources: http://www.x-gen.us/wp-content/uploads/sites/21/2014/03/XGSS_TSM_AMPH.03.15.pdf	Curative	Approved 8583	AMPHOTERICIN B Approved Use Amphotericin B for Injection USP should be administered primarily to patients with progressive, potentially life-threatening fungal infections. This potent drug should not be used to treat noninvasive fungal infections, such as oral thrush, vaginal candidiasis and esophageal candidiasis in patients with normal neutrophil counts. Amphotericin B for Injection USP is specifically intended to treat potentially life-threatening fungal infections: aspergillosis, cryptococcosis (torulosis), North American blastomycosis, systemic candidiasis, coccidioido-mycosis, histoplasmosis, zygomycosis including mucormycosis due to susceptible species of the genera Absidia, Mucor and Rhizopus, and infections due to related susceptible species of Conidiobolus and Basidiobolus, and sporotrichosis. Amphotericin B may be useful in the treatment of American mucocutaneous leishmaniasis, but it is not the drug of choice as primary therapy. Launch Date 1992
Zygomycosis 3 Sources: http://www.x-gen.us/wp-content/uploads/sites/21/2014/03/XGSS_TSM_AMPH.03.15.pdf	Curative	Approved 8583	AMPHOTERICIN B Approved Use Amphotericin B for Injection USP should be administered primarily to patients with progressive, potentially life-threatening fungal infections. This potent drug should not be used to treat noninvasive fungal infections, such as oral thrush, vaginal candidiasis and esophageal candidiasis in patients with normal neutrophil counts. Amphotericin B for Injection USP is specifically intended to treat potentially life-threatening fungal infections: aspergillosis, cryptococcosis (torulosis), North American blastomycosis, systemic candidiasis, coccidioido-mycosis, histoplasmosis, zygomycosis including mucormycosis due to susceptible species of the genera Absidia, Mucor and Rhizopus, and infections due to related susceptible species of Conidiobolus and Basidiobolus, and sporotrichosis. Amphotericin B may be useful in the treatment of American mucocutaneous leishmaniasis, but it is not the drug of choice as primary therapy. Launch Date 1992
Mucormycosis 3 Sources: http://www.x-gen.us/wp-content/uploads/sites/21/2014/03/XGSS_TSM_AMPH.03.15.pdf	Curative	Approved 8583	AMPHOTERICIN B Approved Use Amphotericin B for Injection USP should be administered primarily to patients with progressive, potentially life-threatening fungal infections. This potent drug should not be used to treat noninvasive fungal infections, such as oral thrush, vaginal candidiasis and esophageal candidiasis in patients with normal neutrophil counts. Amphotericin B for Injection USP is specifically intended to treat potentially life-threatening fungal infections: aspergillosis, cryptococcosis (torulosis), North American blastomycosis, systemic candidiasis, coccidioido-mycosis, histoplasmosis, zygomycosis including mucormycosis due to susceptible species of the genera Absidia, Mucor and Rhizopus, and infections due to related susceptible species of Conidiobolus and Basidiobolus, and sporotrichosis. Amphotericin B may be useful in the treatment of American mucocutaneous leishmaniasis, but it is not the drug of choice as primary therapy. Launch Date 1992
Sporotrichosis 3 Sources: http://www.x-gen.us/wp-content/uploads/sites/21/2014/03/XGSS_TSM_AMPH.03.15.pdf	Curative	Approved 8583	AMPHOTERICIN B Approved Use Amphotericin B for Injection USP should be administered primarily to patients with progressive, potentially life-threatening fungal infections. This potent drug should not be used to treat noninvasive fungal infections, such as oral thrush, vaginal candidiasis and esophageal candidiasis in patients with normal neutrophil counts. Amphotericin B for Injection USP is specifically intended to treat potentially life-threatening fungal infections: aspergillosis, cryptococcosis (torulosis), North American blastomycosis, systemic candidiasis, coccidioido-mycosis, histoplasmosis, zygomycosis including mucormycosis due to susceptible species of the genera Absidia, Mucor and Rhizopus, and infections due to related susceptible species of Conidiobolus and Basidiobolus, and sporotrichosis. Amphotericin B may be useful in the treatment of American mucocutaneous leishmaniasis, but it is not the drug of choice as primary therapy. Launch Date 1992
Aspergillus infections 4 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/050740s021lbl.pdf	Curative	Approved 8583	AMPHOTERICIN B Approved Use Amphotericin B for Injection USP should be administered primarily to patients with progressive, potentially life-threatening fungal infections. This potent drug should not be used to treat noninvasive fungal infections, such as oral thrush, vaginal candidiasis and esophageal candidiasis in patients with normal neutrophil counts. Amphotericin B for Injection USP is specifically intended to treat potentially life-threatening fungal infections: aspergillosis, cryptococcosis (torulosis), North American blastomycosis, systemic candidiasis, coccidioido-mycosis, histoplasmosis, zygomycosis including mucormycosis due to susceptible species of the genera Absidia, Mucor and Rhizopus, and infections due to related susceptible species of Conidiobolus and Basidiobolus, and sporotrichosis. Amphotericin B may be useful in the treatment of American mucocutaneous leishmaniasis, but it is not the drug of choice as primary therapy. Launch Date 1992

C_max

Value	Dose	Analyte	Population
7.3 μg/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/050740Orig1s031lbl.pdf	1 mg/kg single, intravenous dose: 1 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered:	AMPHOTERICIN B serum	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
17.2 μg/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/050740Orig1s031lbl.pdf	2.5 mg/kg single, intravenous dose: 2.5 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered:	AMPHOTERICIN B serum	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
57.6 μg/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/050740Orig1s031lbl.pdf	5 mg/kg single, intravenous dose: 5 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered:	AMPHOTERICIN B serum	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
12.2 μg/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/050740Orig1s031lbl.pdf	1 mg/kg 1 times / day multiple, intravenous dose: 1 mg/kg route of administration: Intravenous experiment type: MULTIPLE co-administered:	AMPHOTERICIN B serum	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
31.4 μg/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/050740Orig1s031lbl.pdf	2.5 mg/kg 1 times / day multiple, intravenous dose: 2.5 mg/kg route of administration: Intravenous experiment type: MULTIPLE co-administered:	AMPHOTERICIN B serum	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
83 μg/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/050740Orig1s031lbl.pdf	5 mg/kg 1 times / day multiple, intravenous dose: 5 mg/kg route of administration: Intravenous experiment type: MULTIPLE co-administered:	AMPHOTERICIN B serum	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
83.7 μg/mL REVIEW https://www.pmda.go.jp/drugs/2006/P200600024/40009300_21800AMY10095_K254_2.pdf	7.5 mg/kg single, intravenous dose: 7.5 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered:	AMPHOTERICIN B serum	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
62.4 μg/mL REVIEW https://www.pmda.go.jp/drugs/2006/P200600024/40009300_21800AMY10095_K254_2.pdf	7.5 mg/kg 1 times / day multiple, intravenous dose: 7.5 mg/kg route of administration: Intravenous experiment type: MULTIPLE co-administered:	AMPHOTERICIN B serum	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

AUC

Value	Dose	Analyte	Population
27 μg × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/050740Orig1s031lbl.pdf	1 mg/kg single, intravenous dose: 1 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered:	AMPHOTERICIN B serum	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
65 μg × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/050740Orig1s031lbl.pdf	2.5 mg/kg single, intravenous dose: 2.5 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered:	AMPHOTERICIN B serum	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
269 μg × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/050740Orig1s031lbl.pdf	5 mg/kg single, intravenous dose: 5 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered:	AMPHOTERICIN B serum	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
60 μg × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/050740Orig1s031lbl.pdf	1 mg/kg 1 times / day multiple, intravenous dose: 1 mg/kg route of administration: Intravenous experiment type: MULTIPLE co-administered:	AMPHOTERICIN B serum	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
197 μg × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/050740Orig1s031lbl.pdf	2.5 mg/kg 1 times / day multiple, intravenous dose: 2.5 mg/kg route of administration: Intravenous experiment type: MULTIPLE co-administered:	AMPHOTERICIN B serum	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
555 μg × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/050740Orig1s031lbl.pdf	5 mg/kg 1 times / day multiple, intravenous dose: 5 mg/kg route of administration: Intravenous experiment type: MULTIPLE co-administered:	AMPHOTERICIN B serum	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
476 μg × h/mL REVIEW https://www.pmda.go.jp/drugs/2006/P200600024/40009300_21800AMY10095_K254_2.pdf	7.5 mg/kg single, intravenous dose: 7.5 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered:	AMPHOTERICIN B serum	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
382 μg × h/mL REVIEW https://www.pmda.go.jp/drugs/2006/P200600024/40009300_21800AMY10095_K254_2.pdf	7.5 mg/kg 1 times / day multiple, intravenous dose: 7.5 mg/kg route of administration: Intravenous experiment type: MULTIPLE co-administered:	AMPHOTERICIN B serum	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

T_1/2

Value	Dose	Analyte	Population
10.7 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/050740Orig1s031lbl.pdf	1 mg/kg single, intravenous dose: 1 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered:	AMPHOTERICIN B serum	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
8.1 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/050740Orig1s031lbl.pdf	2.5 mg/kg single, intravenous dose: 2.5 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered:	AMPHOTERICIN B serum	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
6.4 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/050740Orig1s031lbl.pdf	5 mg/kg single, intravenous dose: 5 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered:	AMPHOTERICIN B serum	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
7 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/050740Orig1s031lbl.pdf	1 mg/kg 1 times / day multiple, intravenous dose: 1 mg/kg route of administration: Intravenous experiment type: MULTIPLE co-administered:	AMPHOTERICIN B serum	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
6.3 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/050740Orig1s031lbl.pdf	2.5 mg/kg 1 times / day multiple, intravenous dose: 2.5 mg/kg route of administration: Intravenous experiment type: MULTIPLE co-administered:	AMPHOTERICIN B serum	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
6.8 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/050740Orig1s031lbl.pdf	5 mg/kg 1 times / day multiple, intravenous dose: 5 mg/kg route of administration: Intravenous experiment type: MULTIPLE co-administered:	AMPHOTERICIN B serum	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
8.5 h REVIEW https://www.pmda.go.jp/drugs/2006/P200600024/40009300_21800AMY10095_K254_2.pdf	7.5 mg/kg single, intravenous dose: 7.5 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered:	AMPHOTERICIN B serum	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
6.9 h REVIEW https://www.pmda.go.jp/drugs/2006/P200600024/40009300_21800AMY10095_K254_2.pdf	7.5 mg/kg 1 times / day multiple, intravenous dose: 7.5 mg/kg route of administration: Intravenous experiment type: MULTIPLE co-administered:	AMPHOTERICIN B serum	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

F_unbound

Value	Dose	Co-administered	Analyte	Population
2.1% EXPERIMENT https://aac.asm.org/content/46/3/834.long			AMPHOTERICIN B plasma	Homo sapiens

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
			inhibitor 2217

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
MRP3 246 OCT2 779 OAT1 725 BCRP 910 BSEP 550 P-gp 1741 MRP1 116 MRP2 499 MRP4 290 MRP5 31	P-gp 2052

Drug as perpetrator

Target	Modality	Activity
BSEP 554	inhibitor 4027 Sources: https://aac.asm.org/content/60/6/3372.short Page: 3377.0	no
MRP1 232	inhibitor 4027 Sources: https://aac.asm.org/content/60/6/3372.short Page: 3377.0	no
MRP2 625	inhibitor 4027 Sources: https://aac.asm.org/content/60/6/3372.short Page: 3377.0	no
MRP3 326	inhibitor 4027 Sources: https://aac.asm.org/content/60/6/3372.short Page: 3377.0	no
MRP4 345	inhibitor 4027 Sources: https://aac.asm.org/content/60/6/3372.short Page: 3377.0	no
MRP5 80	inhibitor 4027 Sources: https://aac.asm.org/content/60/6/3372.short Page: 3377.0	no
OAT1 730	inhibitor 4027 Sources: https://aac.asm.org/content/58/10/5650.short Page: abstract	no
P-gp 1932	inhibitor 4027 Sources: https://aac.asm.org/content/60/6/3372.short Page: 3377.0	no
BCRP 985	inhibitor 4027 Sources: https://aac.asm.org/content/60/6/3372.short Page: abstract	weak [IC50 127 uM]
OCT2 782	inhibitor 4027 Sources: https://aac.asm.org/content/58/10/5650.short Page: abstract	yes [IC50 7.6 uM]

Drug as victim

Target	Modality	Activity	Metabolite	Clinical evidence
P-gp 2052	substrate 4014 Sources: https://aac.asm.org/content/58/8/4464.short Page: abstract	yes

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 2263	inhibitor 2237 Sources: https://icm-experimental.springeropen.com/articles/10.1186/2197-425X-3-S1-A213 Page: 1.0

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:2682	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:2682
ChemicalBook	CB3425912	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB3425912
eMolecules	30513061	https://www.emolecules.com/cgi-bin/more?vid=30513061
eMolecules	36772192	https://www.emolecules.com/cgi-bin/more?vid=36772192
MolPort	MolPort-006-113-274	https://www.molport.com/shop/molecule-link/MolPort-006-113-274
ZINC	ZINC000253387843	http://zinc15.docking.org/substances/ZINC000253387843

PubMed

Title	Date	PubMed
Bradycardia due to anthracyclines.	1992 Oct 3	1357285
[Drug-induced benign intracranial hypertension. Apropos of a case with amphotericin B. Review of the literature].	1992 Sep-Oct	1299980
Efficacy and Tolerability of Liposomal Amphotericin B (Ambisome) in the Treatment of Visceral Leishmaniasis in Brazil.	1997 Oct	11105143
Risk factors for amphotericin B-induced nephrotoxicity.	1999 Feb	11252333
Successful use of liposomal amphotericin B in a case of amphotericin B-induced nephrogenic diabetes insipidus.	1999 Mar	10194097
Effect of fasting on temporal variation in the nephrotoxicity of amphotericin B in rats.	1999 Mar	10049261
Fluconazole vs low-dose amphotericin B for the prevention of fungal infections in patients undergoing bone marrow transplantation: a study of the North American Marrow Transplant Group.	2000 Apr	10808206
Amiloride for the prevention of amphotericin B-induced hypokalemia and hypomagnesemia.	2000 Jan	10669191
Use of amphotericin B colloidal dispersion in children.	2000 May-Jun	10864055
Failure of pentavalent antimony in visceral leishmaniasis in India: report from the center of the Indian epidemic.	2000 Oct	11049798
Role of humoral mediators in, and influence of a liposomal formulation on, acute amphotericin B nephrotoxicity.	2001 Apr	11322173
Successful unrelated bone marrow transplantation for a patient with chronic granulomatous disease and associated resistant pneumonitis and Aspergillus osteomyelitis.	2001 Jul	11498749
Amphotericin B-induced partial nephrogenic diabetes insipidus in a child.	2001 Jul	11465810
The effect of amiloride on amphotericin B-induced hypokalaemia.	2001 Jul	11418519
[Pulmonary mucormycosis: benefit of aerosol amphotericin B?].	2001 Jun	11468594
Mortality and costs of acute renal failure associated with amphotericin B therapy.	2001 Mar 1	11229835
Amphotericin B-induced seizures in a patient with AIDS.	2001 Sep	11573852
A prospective and retrospective analysis of the nephrotoxicity and efficacy of lipid-based amphotericin B formulations.	2001 Sep	11560200
Persistent acute tubular toxicity after switch from conventional amphotericin B to liposomal amphotericin B (Ambisome).	2003 Feb	12562731
In vitro susceptibility of Aspergillus spp. clinical isolates to albendazole.	2003 Jun	12716778
Single-dose liposomal amphotericin B in the treatment of visceral leishmaniasis in India: a multicenter study.	2003 Sep 15	12955641
Successful treatment with micafungin of invasive pulmonary aspergillosis in acute myeloid leukemia, with renal failure due to amphotericin B therapy.	2004 Jan	14661114
Reversible dilated cardiomyopathy related to amphotericin B therapy.	2004 Jan	14657095
Efficacy and safety of amphotericin B lipid complex in 548 children and adolescents with invasive fungal infections.	2005 Feb	15702047
Candida glabrata prosthetic valve endocarditis treated successfully with fluconazole plus caspofungin without surgery: a case report and literature review.	2005 Nov	16283214
[Amphotericin B associated with hypertension: haemodynamic profile].	2005 Nov-Dec	16183243
Use of Leishmania donovani field isolates expressing the luciferase reporter gene in in vitro drug screening.	2005 Sep	16131481
Amphotericin B-induced severe hypertension in a young patient: case report and review of the literature.	2006	16538979
Amphotericin B blunts erythropoietin response to hypoxia by reinforcing FIH-mediated repression of HIF-1.	2006 Feb 1	16189267
An unusual presentation of rhinofacial zygomycosis due to Cunninghamella sp. in an immunocompetent patient: a case report and literature review.	2006 Jan	16390472
Visceral leishmaniasis (kala-azar)--the Bihar (India) perspective.	2006 Jul	16269185
In vitro efficacy of corifungin against Acanthamoeba castellanii trophozoites and cysts.	2014	24366747

Patents

Sample Use Guides

In Vivo Use Guide

Mice were treated intraperitoneally once daily with 9 mg/kg of corifungin for 10 days. In rats, corifungin is safe up to a level of 250 mg/kg/day when administered by oral gavage for 28 days

Route of Administration: Other

In Vitro Use Guide

200 uM corifungin induces subcellular damage to A. castellanii (the presence of swollen mitochondria, electron-dense granules, degeneration of cytoplasm architecture, and loss of nuclear chromatin structure)

Substance Class	Chemical Created by `admin` on `Wed Apr 02 15:57:55 GMT 2025` Edited by `admin` on `Wed Apr 02 15:57:55 GMT 2025`
Record UNII	44WG8E9MTU
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

Amphotericin B deoxycholate [WHO-DD]

Preferred Name

English

Amphotericin B deoxycholate

Common Name

English

Code System Code Type Description

PUBCHEM

23668620